Loading
A phase 1/2 trial of Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed and Cetuximab in advanced solid tumours, run by D3 Bio (Wuxi) Co., Ltd, now recruiting.
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation is a phase 1/2 interventional study registered as NCT05410145 by D3 Bio (Wuxi) Co., Ltd, with 442 participants planned, started 2022-08-03 and due to reach its primary completion in 2027-04. Interventions recorded: D3S-001, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed and Cetuximab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Cetuximab, Pemetrexed, Cisplatin, Carboplatin and the tag pipeline.
Shares D3 Bio (Wuxi), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Cetuximab, Pemetrexed, Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Cetuximab, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/